Phase 4 N=19 Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury.
Spinal Cord Injury · Pain
Primary: Numerical Rating Scale-NRS — 4.50; 3.44 units on a scale — p=0.432
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)
Polycystic Ovarian Syndrome · Vitamin D Deficiency
Primary: Serum HbA1C at 3 Months — 5.55 percentage
Phase 3 N=49 Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)
Asthma
Primary: Number of Participants With At Least One Adverse Event (AE) — 5; 8 participants
Phase 2 N=71 Balloon REmodeling Antrostomy THErapy Study
Sinusitis
Primary: Incidences of Device-related or Procedure-related Complications — 1 participants
Phase 2 N=20 Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants
Preterm Infants
Primary: Baseline Retic Count — 122; 140 x1000 cells/microliter
Phase 3 N=38 ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals
Opiate Dependence
Primary: Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study. — 37 participants
Phase 2 N=78 Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants
Pain · Cancer
Primary: Percentage of Participants With Sustained Pain Control for 5 Day Fixed Dose Phase — 89.7; 92.9 percentage of participants
Phase 1 N=22 Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Cancer Patients
Carcinoma
Primary: the Number of Lymph Nodes: 1. Identified Within Each Lymph Node Group, 2.Located Within the Submandibular Gland, and 3. Within the Fibrofatty Contents Lying Deep to the…
Phase 3 N=61 Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder
Chronic Motor or Vocal Tic Disorder · Tourette's Disorder
Primary: Mean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7) — -9.62; -14.97 units on a scale
Phase 2 N=59 Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression-Free Survival (PFS) — 41; 44 percentage of participants
Phase 3 N=108 Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)
Type 2 Diabetes
Primary: Change in HbA1c Baseline to End of Trial in TINSAL-T2D Stage 1 — -0.36; -0.34; -0.49; -0.01 % (units of HbA1c) — p=<0.05
Phase 4 N=276 Aminotransferase Trends During Prolonged Acetaminophen Dosing
Drug Toxicity · Healthy
Primary: The Proportion of Subjects Treated With Long-term Acetaminophen (4 g/Day) That Develops Persistent ALT Elevations. — 204; 47; 1; 0 participants
Phase 3 N=55 A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection
Mycoses · Candidiasis · Aspergillosis
Primary: Maximum Plasma Itraconazole Concentration (Cmax) — 2.90; 2.30; 1.79; 9.20 mcg/ml
Phase 4 N=80 An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
Schizophrenia · Schizophreniform Disorder · Schizoaffective Disorder
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 68.9; 28.1 Units on a scale
Phase 2 N=13 Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Hematologic Malignancies
Primary: The Maximally Tolerated Dose (MTD) of Bortezomib (Velcade) That Can be Administered With Tacrolimus and Methotrexate After Mismatched Allogeneic Non-myeloablative…